Cellectar Biosciences reported strong Phase 2b data for its cancer drug iopofosine I 131 in treating Waldenström macroglobulinemia, showing high response rates and durable outcomes in difficult cases. The company is on track to start dosing patients in a confirmatory Phase 3 trial in early 2027 and plans to submit for accelerated FDA approval in the first half of 2027. Additionally, a case study showed an eight-year complete response in a lymphoma patient, highlighting the drug's potential. Cellectar also raised $31.7 million in May 2026 and has sufficient cash to fund operations into mid-2027, supporting ongoing trials and development.
Cellectar Biosciences' recent financial and clinical updates provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced US health-sector stocks, 85 rose and 56 fell. Notable movers include Canopy Growth Corp (CGC) at USD 0.65 with a 1-day change of +4.37%, AbCellera Biologics Inc (ABCL) at USD 12.96 up +3.68%, and Liquidia Corporation (LQDA) at USD 49.03 with a +2.42% change.
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
Viasat has been awarded a $450 million IDIQ contract by the U.S. Space Force to support the design, development, and sustainment of the Space Data Network Backbone (SDN-B) mission operations center. This network aims to provide resilient, high-capaci...
